Harriet M. Kluger
Yale Cancer Center · 842 works · 32,468 citations · h-index 80
Top works
- Nivolumab plus Ipilimumab in Advanced Melanoma
- Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab
- PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma
- Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma
- Precipitation of Autoimmune Diabetes With Anti-PD-1 Immunotherapy
- Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial
- Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic melanoma (mM).
- Survival, response duration, and activity by BRAF mutation (MT) status of nivolumab (NIVO, anti-PD-1, BMS-936558, ONO-4538) and ipilimumab (IPI) concurrent therapy in advanced melanoma (MEL).
- Survival, Durable Response, and Long-Term Safety in Patients With Previously Treated Advanced Renal Cell Carcinoma Receiving Nivolumab
- Combination Therapy with Anti–CTLA-4 and Anti–PD-1 Leads to Distinct Immunologic Changes In Vivo
- Collateral Damage: Insulin-Dependent Diabetes Induced With Checkpoint Inhibitors
- Expression Profiling Reveals Novel Pathways in the Transformation of Melanocytes to Melanomas
- Expression profiling reveals novel pathways in the transformation of Melanocytes to Melanomas.
- Long-term survival of ipilimumab-naive patients (pts) with advanced melanoma (MEL) treated with nivolumab (anti-PD-1, BMS-936558, ONO-4538) in a phase I trial.
- Survival and long-term follow-up of safety and response in patients (pts) with advanced melanoma (MEL) in a phase I trial of nivolumab (anti-PD-1; BMS-936558; ONO-4538).
- Survival and long-term follow-up of safety and response in patients (pts) with advanced melanoma (MEL) in a phase I trial of nivolumab (anti-PD-1; BMS-936558; ONO-4538).
- Immunomodulatory Activity of Nivolumab in Metastatic Renal Cell Carcinoma
- Incidence of the V600K mutation among melanoma patients with BRAF mutations, and potential therapeutic response to the specific BRAF inhibitor PLX4032
- Exome sequencing identifies recurrent mutations in NF1 and RASopathy genes in sun-exposed melanomas
- Lifileucel, a Tumor-Infiltrating Lymphocyte Therapy, in Metastatic Melanoma